...
首页> 外文期刊>Clinical journal of the American Society of Nephrology: CJASN >Revisiting the Dialysate Sodium Prescription as a Tool for Better Blood Pressure and Interdialytic Weight Gain Management in Hemodialysis Patients
【24h】

Revisiting the Dialysate Sodium Prescription as a Tool for Better Blood Pressure and Interdialytic Weight Gain Management in Hemodialysis Patients

机译:重新审视透析液钠处方作为改善血液透析患者血压和透析间体重增加的工具

获取原文

摘要

Hypertension and chronic volume overload are complications often seen in hemodialysis patients. Current hemodialysis practices adopt a standard dialysate sodium prescription that is typically higher than the plasma sodium concentration of most patients. As a general rule, hemodialysis patients have stable predialysis plasma sodium concentrations, and each patient has a fixed a€?osmolar set point.a€? Hypertonic dialysate sodium prescriptions, including sodium modeling, predispose to positive sodium balance and lead to higher blood pressure and increased interdialytic weight gain. Conversely, lowering or individualizing dialysate sodium reduces thirst, interdialytic weight gain, and blood pressure in non-hypotension prone dialysis patients. Optimization of the dialysate sodium prescription is an important step in achieving sodium balance and improving blood pressure control in hypertensive hemodialysis patients.
机译:高血压和慢性容量超负荷是血液透析患者中​​常见的并发症。当前的血液透析实践采用标准的透析液钠处方,该处方通常高于大多数患者的血浆钠浓度。通常,血液透析患者的透析前血浆钠浓度稳定,每位患者的血浆渗透压设定点均固定。高渗透析液钠处方(包括钠建模)容易使钠平衡达到正值,并导致血压升高和透析间体重增加。相反,降低或个性化的透析液钠可降低非低血压倾向性透析患者的口渴,透析间体重增加和血压。优化透析液钠处方是实现高血压血液透析患者钠平衡和改善血压控制的重要步骤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号